Contenu disponible en anglais seulement.
Bulletin de la Bourse
Satellos Bioscience Inc. (MSCL) inscrit à la Bourse de Toronto
13 février 2024
| Issuer: | Satellos Bioscience Inc. (the "Company") |
| Security: | Common shares |
| Symbol(s): | MSCL |
| Number of securities issued and outstanding: | 112,791,658 |
| Number of securities reserved for issuance: | 70,349,199 |
| Listing category: | Industrial, Non-Exempt Issuer |
| Trading currency: | CDN$ |
| Listing and posted for trading date: | February 15, 2024 (at the opening) |
| Other market(s): | The common shares have been listed on the TSX Venture Exchange ("TSXV") since August 18, 2021 under the symbol "MSCL". The common shares will be delisted from the TSXV on February 15, 2024, upon commencement of trading on the ÍÃ×ÓÏÈÉú. |
| Temporary market maker: | Research Capital Corporation |
| Investor relations: | Elizabeth Williams Chief Financial Officer (416) 648-5555 Email: lwilliams@satellos.com -or- Frank Gleeson Chief Excecutive Officer (905) 336-6128 Email: fgleeson@satellos.com |
| Incorporation: | Canada Business Corporations Act |
| Fiscal year end: | December 31 |
| Nature of business: | The Company is a biotechnology company dedicated to developing medicines to treat degenerative muscle diseases. The Company's lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. |
| Transfer agent and registrar: | Computershare Investor Services Inc., at its principal office in Vancouver. |
| Dividends: | The Company does not anticipate paying cash dividends on the common shares in the foreseeable future. |
| Sponsorship: | Not applicable. |
| TSX contact: | Selma Thaver, Managing Director, TSX Listings |